Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan plus dapagliflozin in cirrhosis with portal hypertension (CTR20233552)
CTR20233552Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zibotentan, dapagliflozin in Cirrhosis, Portal Hypertension (PH), sponsored by AstraZeneca. Started Nov 2023; status: terminated.
02
Drugs
zibotentandapagliflozin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on CTR20233552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233552.